We are reaffirming a buy for S&P Global (SPGI) due to strong fundamentals, robust growth potential, AI initiatives, and ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...

Breast cancer survivors who developed incident myocardial infarction or heart failure exhibited increased risk for adverse oncologic outcomes, according to a population-based cohort study.The findings ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

HealthDay News — For infants born before 34 weeks of gestation and with a birth weight less than 1000g, probiotics used in neonatal units are associated with reduced mortality, according to a study ...

Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Epidural steroid injections demonstrated limited efficacy in reducing back pain and disability, according to a systematic ...

An overall increase in life expectancy was observed across all individuals living with HIV but disparities between gender groups persist.